732 related articles for article (PubMed ID: 34057395)
1. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
[No Abstract] [Full Text] [Related]
2. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.
Sellers J; Darby RR; Farooque A; Claassen DO
Drugs Aging; 2019 Jul; 36(7):647-653. PubMed ID: 30924099
[TBL] [Abstract][Full Text] [Related]
3. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N
Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863
[TBL] [Abstract][Full Text] [Related]
4. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Wilby KJ; Johnson EG; Johnson HE; Ensom MHH
Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039
[TBL] [Abstract][Full Text] [Related]
5. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.
Mosholder AD; Ma Y; Akhtar S; Podskalny GD; Feng Y; Lyu H; Liao J; Wei Y; Wernecke M; Leishear K; Nelson LM; MaCurdy TE; Kelman JA; Graham DJ
Am J Psychiatry; 2022 Aug; 179(8):553-561. PubMed ID: 35702829
[TBL] [Abstract][Full Text] [Related]
6. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
[TBL] [Abstract][Full Text] [Related]
7. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
Mathis MV; Muoio BM; Andreason P; Avila AM; Farchione T; Atrakchi A; Temple RJ
J Clin Psychiatry; 2017 Jun; 78(6):e668-e673. PubMed ID: 28493654
[TBL] [Abstract][Full Text] [Related]
8. Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
Espay AJ; Guskey MT; Norton JC; Coate B; Vizcarra JA; Ballard C; Factor SA; Friedman JH; Lang AE; Larsen NJ; Andersson C; Fredericks D; Weintraub D
Mov Disord; 2018 Nov; 33(11):1769-1776. PubMed ID: 30387904
[TBL] [Abstract][Full Text] [Related]
9. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
Isaacson SH; Ballard CG; Kreitzman DL; Coate B; Norton JC; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
Parkinsonism Relat Disord; 2021 Jun; 87():25-31. PubMed ID: 33933853
[TBL] [Abstract][Full Text] [Related]
10. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Kianirad Y; Simuni T
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
[TBL] [Abstract][Full Text] [Related]
11. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
[TBL] [Abstract][Full Text] [Related]
12. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
[TBL] [Abstract][Full Text] [Related]
13. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
Ballard C; Isaacson S; Mills R; Williams H; Corbett A; Coate B; Pahwa R; Rascol O; Burn DJ
J Am Med Dir Assoc; 2015 Oct; 16(10):898.e1-7. PubMed ID: 26239690
[TBL] [Abstract][Full Text] [Related]
14. Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.
Yuan M; Sperry L; Malhado-Chang N; Duffy A; Wheelock V; Farias S; O'Connor K; Olichney J; Shahlaie K; Zhang L
Brain Behav; 2017 Jun; 7(6):e00639. PubMed ID: 28638698
[TBL] [Abstract][Full Text] [Related]
15. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
Majlath Z; Obal I; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
[TBL] [Abstract][Full Text] [Related]
16. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
[TBL] [Abstract][Full Text] [Related]
17. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
18. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
Isaacson SH; Coate B; Norton J; Stankovic S
J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320
[TBL] [Abstract][Full Text] [Related]
19. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
[TBL] [Abstract][Full Text] [Related]
20. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
Duits JH; Ongering MS; Martens HJM; Schulte PFJ
Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]